Directed therapies in lung cancer: new hope?

Arch Bronconeumol. 2012 Oct;48(10):367-71. doi: 10.1016/j.arbres.2012.03.007. Epub 2012 Apr 30.
[Article in English, Spanish]

Abstract

Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK).

Publication types

  • Review

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibody Specificity
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / epidemiology
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Forecasting
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / epidemiology
  • Lung Neoplasms / genetics
  • Lung Neoplasms / surgery
  • Molecular Targeted Therapy*
  • Multicenter Studies as Topic
  • Neoplasm Proteins / antagonists & inhibitors
  • Oncogene Proteins, Fusion / antagonists & inhibitors
  • Prospective Studies
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • EML4-ALK fusion protein, human
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Vascular Endothelial Growth Factor A
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • ErbB Receptors
  • Receptor Protein-Tyrosine Kinases